Valuation: FamiCord AG

Market Cap 52.99M 59.34M 49.44M 44.91M 84.51M 5.75B 85.33M 594M 232M 2.92B 223M 218M 9.39B P/E 2026 *
304x
P/E 2027 * 50.7x
Enterprise Value 60.99M 68.3M 56.9M 51.69M 97.26M 6.61B 98.21M 683M 267M 3.36B 256M 251M 10.81B EV / Sales 2026 *
0.72x
EV / Sales 2027 * 0.67x
Free-Float
26.82%
Yield 2026 *
-
Yield 2027 * -
1 day-8.55%
1 week-8.55%
Current month-8.55%
1 month-8.55%
3 months-8.55%
6 months-51.37%
Current year-51.37%
1 month 3.1
Extreme 3.1
3.1
Current year 3.1
Extreme 3.1
3.39
1 year 3.1
Extreme 3.1
7
3 years 3.1
Extreme 3.1
9
5 years 3.1
Extreme 3.1
9
10 years 3.1
Extreme 3.1
19.45
Manager TitleAgeSince
Chief Executive Officer 55 22/03/2022
Director of Finance/CFO 53 01/08/2024
Chief Tech/Sci/R&D Officer - 01/03/2025
Director TitleAgeSince
Chairman 62 28/06/2017
Director/Board Member - 01/01/2017
Director/Board Member 54 01/12/2021
Change 5-day change 1-year change 3-year change Capi.($)
-8.55%-8.55% - - 59.31M
-0.17%+3.05%+14.13%+23.23% 112B
+1.33%+5.11%+4.40%+78.75% 95.08B
-1.21%-4.33%+127.08%+808.60% 57.02B
-4.53%-2.18%-5.47%+55.95% 27.29B
+0.71%+3.15%+13.22%+55.23% 25.3B
+1.65%-0.12%+27.60%+84.90% 25.06B
+0.26%+0.97%-15.92%-3.09% 21.27B
+0.28%+2.60%+29.97%+324.73% 20.92B
+2.61%+18.47%+11.12%+85.92% 19.35B
Average -1.26%+1.78%+22.90%+168.25% 44.86B
Weighted average by Cap. -1.37%+1.47%+26.34%+172.49%

Financials

2026 *2027 *
Net sales 85M 95.18M 79.3M 72.03M 136M 9.22B 137M 952M 372M 4.68B 357M 350M 15.07B 88.4M 98.99M 82.47M 74.91M 141M 9.59B 142M 990M 387M 4.87B 372M 364M 15.67B
Net income 300K 336K 280K 254K 478K 32.54M 483K 3.36M 1.31M 16.53M 1.26M 1.23M 53.17M 1M 1.12M 933K 847K 1.59M 108M 1.61M 11.2M 4.38M 55.11M 4.2M 4.11M 177M
Net Debt 8M 8.96M 7.46M 6.78M 12.76M 868M 12.88M 89.6M 35.05M 441M 33.64M 32.91M 1.42B 6M 6.72M 5.6M 5.08M 9.57M 651M 9.66M 67.2M 26.28M 331M 25.23M 24.68M 1.06B
Projected Income Statement - Annual - FamiCord AG
Logo FamiCord AG
FamiCord AG, formerly Vita 34 AG, is a Germany-based company operating in the medical technology sector and acts as a cell bank/stem bank. The Company is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected during the child’s birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after brain injuries, cartilage damages and others. The cells also allow the growing of whole organs, such as the liver. On an average, one out of seven individuals, whose cells are sorted, receives autologous stem cell transplant by age of 70. The Company acts as a cord blood bank and is also engaged in research activities around regenerative medicine, including curing the consequences of strokes and heart attacks. The Company operates in Germany, Spain and Denmark.
Employees
684
Date Price Change Volume
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.040EUR
Average target price
6.500EUR
Spread / Average Target
+113.82%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - FamiCord AG